The field of RNA-targeted therapeutics is rapidly evolving, offering groundbreaking opportunities for the treatment of a wide array of diseases ...
Marlene Belfort does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...
Phase 2 evaluation of the nilotinib-paclitaxel combination in patients with rare solid tumors: Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors trial 1 (RARE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results